STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

Noopept

Also known as

GVS-111 · DVD-111 · SGS-111 · omberacetam · Omberacetam (INN) · N-phenylacetyl-L-prolylglycine ethyl ester · N-phenylacetylprolylglycine ethyl ester · Benzylcarbonyl-Pro-Gly-OEt · Noopept® · Ноопепт

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Some talk Systemic Oral / Sublingual Cognitive research compounds

CNS-oriented small molecule used mainly by oral or sublingual routes; intranasal use is a minority experiment.

What people say Noopept, or omberacetam, is a synthetic dipeptide-derived small molecule used at low milligram oral doses. Its human clinical history centers on Russian cognitive-impairment cohorts, not well-controlled healthy-user enhancement trials. Doses people talk about
Inspected month-long account5–10 mg insufflated powder three times daily

One user who snorted individually weighed powder described onset within 5–10 minutes, acute effects up to 3–4 hours, persistent calm/focus over a month and no withdrawal; oral had felt ineffective to that person. This high-frequency self-report is not a recommendation.

Inspected adverse account10 mg/day sublingual for 10 days, sometimes split into 5 mg twice one hour apart

The author reported panic at 10 mg at once, sleep loss, tics and impaired short-term memory, with speech effects changing across the ten days.

Clinical cognitive-impairment anchor10 mg twice daily (~20 mg/day) for about 56 days

Used in a Russian comparative study of vascular or post-traumatic mild cognitive disorders; not a healthy-user PK or enhancement trial.

Community modal band~10–30 mg/day total, usually split

Repeated forum and vendor range; route and product differences make it a discussion band rather than a single exposure.

Sublingual discussion~7.5–15 mg per use

Common preference range with claims of greater efficiency than swallowed use; no human bioavailability comparison establishes that claim.

One month-long powder-insufflation account and one 10-day sublingual account reported sharply different outcomes. Product identity, route and co-use prevent mg-for-mg equivalence.

Half-life & effect duration

Half-life in the body
  • Parent Noopept · rodent summariesAbout 5–16 minutes
  • cPG metabolite · rat IV studyAbout 80 minutes
Felt duration people report
  • Acute reportsAbout 1–4 hours of effects; one intranasal account started within 5–10 minutes
  • Continued useCalm or focus over weeks, no response, or cognitive and sleep problems
Timing context & sources
How it may feel Reports range from rapid sensory clarity, calm focus and verbal fluency to no effect, irritability, panic, poorer short-term memory and sleep loss. Some users describe a 1–4-hour work window; others say effects change only after days or weeks.
Cycles people discuss Clinical narratives use roughly 56-day courses, while community blocks range from several weeks to continuous use with breaks. Tolerance, reverse-tolerance and withdrawal claims conflict and do not establish a standard cycle. Timing Morning and early-afternoon splits are common in the notes; evening use is often avoided because of insomnia, vivid dreams or delayed sleep onset. Responses vary, and this is not a validated cutoff. Stacks Choline donors, caffeine/L-theanine and Semax commonly accompany Noopept. Co-use may change headache, stimulation, mood and sleep, so stack reports cannot isolate the molecule. Watch for Mood polarity: Clinical literature stresses anxiolytic components; community splits between calmer baseline vs anxiogenic overstim — individual variation dominates.
Related
SemaxTAK-653

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A reviewed human parent half-life is not established by the accessible clinical report.

The Neznamov comparative study documents clinical use in impaired cohorts but does not supply a human analyte-specific PK estimate in the accessible record. Rat and rabbit numbers cannot be relabeled as human oral PK.

The clinical paper is not a dedicated PK study, the evidence base is concentrated in the originating Russian program, and accessible indexed material does not provide route/dose/analyte context for a human half-life number.

Half-life in the body

A rat IV tracer study reported an 80-minute terminal beta phase for cPG, not for human oral parent Noopept.

Kovalev et al. administered 5.7 µg tritium-labeled cPG by IV bolus and fitted a two-compartment model, reporting a one-minute distribution phase and 80-minute terminal elimination phase.

Only three male Wistar rats, with a different compound, species and route from consumer Noopept; radiolabel behavior may include labeled products, and the result cannot establish oral human parent or felt duration.

  • The Study of tritium-labeled Cycloprolylglycine Pharmacokinetics in Rat Blood (opens in a new tab)Study abstract and methods: three male Wistar rats received 5.7 µg tritium-labeled cPG by IV bolus; a two-compartment model gave a one-minute alpha distribution phase and an 80-minute terminal beta elimination phase in blood.Only three animals; cPG tracer in male Wistar rats by IV bolus, not parent Noopept in humans by oral, sublingual or nasal routes. Radiolabel measurements cannot establish felt duration.

Felt duration people report

Reports conflict between a rapid 1–4-hour effect, cumulative multi-week changes, no response and adverse cognitive or sleep effects.

A month-long user who snorted individually weighed powder described onset within 5–10 minutes and up to 3–4 hours of acute effects with longer-term calm/focus. A 10-day sublingual user sometimes split 10 mg/day into two 5 mg uses one hour apart and reported persistent sleep loss, panic at 10 mg at once and changing speech effects; other thread participants described oral benefit.

Anonymous unblinded reports, inconsistent route and product, no assay or standardized cognitive testing, and co-use of modafinil or other nootropics in some accounts.

  • What's your experience with using Noopept long-term? (opens in a new tab)Same-author month-long account: 5–10 mg of individually weighed powder insufflated three times daily, onset within 5–10 minutes and acute effects up to 3–4 hours, with a one-time increase to 15 mg producing diminishing returns, longer-term calm/focus but less color/motivation; no withdrawal on stopping and later occasional racetam co-use. Another user reported oral benefit and verbal fluency.Anonymous uncontrolled accounts with unverified product, high-frequency powder insufflation, no objective testing and modafinil, racetam or other nootropic co-use in the thread.
  • 10 day trial of 10 mg sublingual Noopept results (opens in a new tab)Original 10-day diary and same-author replies: 10 mg sublingual daily, sometimes split into two 5 mg uses; reported panic at 10 mg at once, all-course sleep loss, increased tics, short-term-memory problems and changing speech effects across days.Single self-report after only a 1.5-day washout from prior nootropics, no blinded rechallenge, product assay, clinical assessment or objective cognitive baseline.

What people say 14

  • Focus / sustained attention: Cleaner task stickiness without classic stim jitter for many logs; still confounded by caffeine and sleep. forum
  • Memory / learning (healthy-user anecdote): Easier encoding, recall, and study retention over multi-day to multi-week windows — not placebo-controlled. anecdote
  • Verbal fluency: Repeated self-reports of freer speech, idea generation, and word-finding under social or writing load. forum
  • Null / non-responders: Large minority report nothing at 10–20 mg; authenticity, route, expectation of stimulant “kick,” and sleep often debated. forum
  • Stack confound: Benefits frequently co-credited to Alpha-GPC/CDP-choline, caffeine + L-theanine, Semax/Selank, or other racetams. forum
  • Mild calm / anxiolytic component: Trial literature describes an anxiolytic or emotional-stabilizing element alongside cognition in impaired cohorts; community is mixed (calm vs overstim). trial
  • Clinical MCI (Neznamov & Teleshova 2008, PMID 18697252): Noopept 10 mg twice daily (~20 mg/day) for ~56 days in mild-to-moderate vascular/post-traumatic cognitive impairment; authors reported efficacy at least comparable to piracetam, with stronger signals in some asthenic and post-concussional subgroups; MMSE in treated group described rising roughly from ~26 to ~29 in secondary summaries. trial
  • Stroke-adjacent open series (Amelin et al. 2011, PMID 22500312): ~60 post-stroke patients at about 20 mg/day with reported cognitive improvement and “high level of safety” language — open prospective, not large RCT. trial
  • EEG / clinical characterization (Bochkarev et al. 2008, PMID 19008801): Nonspecific cortical activation plus anxiolytic-profile description in post-traumatic and vascular MCI. trial
  • Neuroprotection (animal): Lower injury markers and preserved function after excitotoxic/ischemic insults; photo-thrombosis cortical damage reduction in originator work. animal
  • In-vitro neuronal survival: Dose-dependent protection under oxidative (H₂O₂) challenge; IC₅₀-class figures around ~1.21 µM in one survival assay (PMID 12711349 class summaries). lab
  • cPG / AMPA narrative: Metabolite cycloprolylglycine framed as endogenous positive AMPA modulator with neurotrophic signaling — used to explain effects after parent clearance. animal
  • Vs piracetam (trial + community): Similar clinical goals at ~1000× lower mg; community often prefers Noopept for convenience and subtler feel, not proven superiority for healthy brains. trial
  • BDNF / NGF (rodent): Ostrovskaya et al. (PMID 19240853) and related work: increased hippocampal NGF and BDNF expression after Noopept — chronic more than single-dose framing in community retellings. animal

Doses people talk about 14

  • Community modal band: ~10–30 mg/day total, usually split into 2–3 small doses — the figure vendors and forums repeat most. forum
  • Beginner / first exposure: Often ~10 mg once daily (oral or sublingual) for several days to watch headache, stim, and sleep before adding a second dose. forum
  • Sublingual preference band: Many logs favor ~7.5–15 mg sublingual as “more efficient” than oral; ~10 mg under tongue is a common single-dose report; some claim oral needs ~20 mg for a comparable feel — preference lore, not proven human BA math. forum
  • Oral standard community schedule: ~10 mg morning + ~10 mg early afternoon (matching trial split) is the most-copied day structure. forum
  • Split 2–3× daily convention: Short parent clearance + desire for daytime coverage drive AM/midday (± early PM) splits rather than once-weekly depot logic. forum
  • Upper community talk: ~30 mg/day is a frequently cited soft ceiling in secondary guides (“do not exceed 30 mg/day”); above that, irritability, overstim, and sleep complaints rise in logs. forum
  • Higher sporadic logs: Occasional 30 mg single-dose or multi-racetam-day experiments appear on forums — not trial-validated and often noisier for sides. anecdote
  • Dose-specificity lore: A minority claim a narrow personal “sweet spot” (including body-weight talk such as ~0.08 mg/kg in one sublingual thread) with effects reversing outside it — highly individual anecdote, not a validated U-curve. anecdote
  • Vendor capsule sizes: 10 mg tablets (Russian-style) and 10–30 mg research capsules common; unit strength ≠ optimal dose. forum
  • Uncertainty: Without COA/HPLC, labeled mg, enantiomer story, and actual fill are vendor-trust issues; teaspoon estimates of powder are discouraged in every serious guide. forum
  • Clinically studied anchor (Neznamov & Teleshova 2008): 10 mg twice daily = ~20 mg/day oral for roughly 56 days in vascular/post-traumatic MCI (PMID 18697252). trial
  • Russian package / product-style narrative: Secondary English inserts describe normal daily dose ~20 mg as 10 mg morning + 10 mg afternoon; course length often 1.5–3 months with optional later re-courses. trial
  • Framing: Research and community discussion ranges only — not advice, prescriptions, or Western regulatory dosing. Powder purity and capsule fill make labeled mg soft. forum
  • Animal mg/kg gap: Preclinical antiamnesic and neuroprotective work spans roughly ~0.1–10 mg/kg class bands depending on model — does not map cleanly to human 10–30 mg practice. animal

How it may feel 8

  • Minutes 15–60 (oral/sublingual): Common subjective onset window — subtle clarity, mild stimulation, sensory “on,” or nothing; sublingual lore claims faster onset than swallow, without human PK proof of superiority. forum
  • Hours 1–4: Working-block focus window often claimed; short parent half-life means people attribute duration to downstream signaling, not depot plasma levels. forum
  • Day 1: Mild focus edge, headache, irritability, or flat response; first check for stim sensitivity and sleep if dosed late. forum
  • Days 1–3: Headache, edginess, GI, or sleep sensitivity show up early for susceptible users; many decide keep/adjust/stop here. forum
  • Week 1–2: Usual healthy-user keep-or-stop window for focus/memory vs overstimulation or null. forum
  • Tolerance / reverse-tolerance debate: Some claim multi-week continuous use dulls the edge; others describe reverse tolerance or delayed “unlock” after choline correction — both are anecdote, not PK-proven. forum
  • Days 5–7: Secondary Russian product narratives say therapeutic effect in patients may appear from ~5–7 days — community often uses week-1 as first productivity checkpoint. trial
  • Weeks 3–8: Trial courses (~56 days) and community multi-week blocks; more stable “noise floor” talk rather than a daily high. trial

Cycles people discuss 10

  • Community multi-week blocks: 4–8 weeks on is the most common “serious course” template among forum users. forum
  • Study / exam pulses: 1–2 week (sometimes ~5–14 day) runs around exams or deep-work sprints — demand-driven rather than open-ended. forum
  • 28-day NGF-trial imitation logs: Some users deliberately copy multi-week ~10 mg daily schedules and report memory change without classic withdrawal. anecdote
  • Continuous vs pulsed: Both exist — daily open-ended for months vs on-demand only; continuous healthy-user safety is not trial-characterized. forum
  • Time off: Days to several weeks between blocks to reassess sleep, irritability, tolerance claims, and whether benefit returns. forum
  • Cycling rationale (community): Tolerance-blunting and “reset” stories compete with reverse-tolerance / potentiation-over-time stories — no single standardized schedule. forum
  • Re-runs: Common for later academic or work spikes; cumulative multi-year risk tables for Western gray-market use are missing. forum
  • With stacks: Often same calendar as choline support and study stimulants; peptide pairs (Semax/Selank) may share the on-window. forum
  • Trial-length courses: ~56-day (~8-week) continuous twice-daily dosing in the flagship MCI comparator narrative. trial
  • Russian product course talk: Often ~1.5–3 months on, with optional second courses after a break in secondary insert summaries. trial

Timing 10

  • Onset: Subjective oral/sublingual onset usually under 1 hour (~15–60 min modal talk). forum
  • Split dosing logic in community talk: AM + early-afternoon dosing aims to cover daytime function and is explained through presumed rapid clearance, rather than multi-day half-life claims. This is a reported rationale, not a schedule established by measured human parent elimination. forum
  • Evening dosing: Evening use is widely avoided in community reports because of insomnia, vivid dreams or delayed sleep onset. The accompanying explanation that the parent is already “long gone” is an assumption, not a measured human clearance result. forum
  • Interindividual variability: Same mg can feel stimulatory, calming, or null across users — stacks and expectation amplify noise. forum
  • Parent half-life (rodent): Often cited ~5–16 minutes class in secondary sources (Examine-style ~16 min rat figure appears widely); parent not a multi-hour circulating drug. animal
  • Serum detectability (animal talk): Parent often described as hard to detect within tens of minutes after oral dosing — effects attributed beyond parent plasma. animal
  • Metabolite cPG: Cycloprolylglycine is the named active metabolite; rat PK (Boyko, Zherdev & Shevchenko 2018, PMID 30378564) models short terminal half-life on the order of ~80 minutes for plasma cPG — refutes “long half-life Noopept” forum claims. animal
  • Why effects can outlast PK: Downstream BDNF/NGF and AMPA/neurotrophic signaling are the proposed durable mechanism, not a long-circulating parent depot. animal
  • Human PK gap: As of major secondary reviews, human metabolism/elimination half-life remains poorly characterized vs animal data. trial
  • “Long half-life” myth: Community and vendor copy sometimes claim long duration from blood levels; rat PK + metabolite clearance contradict that framing. animal

More on what it is 7

  • Why people care: Steady mid-tier r/Nootropics staple: “racetam-class” focus/memory talk at ~10–30 mg/day instead of gram-scale piracetam, plus Russian pharmacy/tablet history that most gray-market nootropics lack. forum
  • Potency meme: “~1000× more potent than piracetam” is a dose-scale slogan (tens of mg vs grams) — not a proven 1000× efficacy multiplier in humans. forum
  • Not: Not an amphetamine, not FDA/EMA-approved cognitive enhancement, not an injectable peptide, and not the same molecule as piracetam / phenylpiracetam / oxiracetam / aniracetam. forum
  • Research lens: Western vendor powder/capsules ≠ Russian pharmaceutical Noopept®; purity, fill, and identity are gray-market trust problems — do not fuse capsule labels with trial mg. forum
  • What it is: Synthetic dipeptide-derived nootropic ethyl ester (INN omberacetam; developmental codes GVS-111 / DVD-111) — N-phenylacetyl-L-prolylglycine ethyl ester; piracetam-related goals at low milligram oral doses, not a classic pyrrolidone racetam structure. trial
  • Evidence honesty: Russian open-label / piracetam-comparator MCI and stroke-adjacent courses (e.g. ~20 mg/day oral, multi-week) denser than Western healthy-user RCTs; Zakusov-origin program concentration is a replication caveat, not a known integrity scandal for the main clinical papers. trial
  • Mechanism talk: Rapid conversion (especially CNS) to endogenous cyclic dipeptide cycloprolylglycine (cPG); AMPA/TrkB-linked neuroprotection and BDNF/NGF expression talk dominate secondary reviews; glutamate/Ca²⁺/free-radical “triad” neuroprotection and HIF-1 activator framing also appear in originator literature. animal

Stacks 12

  • + Choline donor (most common “side-management” stack): Alpha-GPC or CDP-choline (citicoline) when headaches appear — racetam-class acetylcholine-demand story; not trial-proven causation. forum
  • Alpha-GPC amounts in logs: Community stacks often land roughly in the ~300–600 mg/day Alpha-GPC band used for general nootropic choline support; some logs run ~500–750 mg with ~10–12 mg Noopept — individual, not a fixed ratio. forum
  • CDP-choline alternative: Citicoline preferred by users who find Alpha-GPC too stimulatory or dulling. forum
  • Choline double-edge: Too little choline → headache lore; too much choline → fog, depression, or blunted clarity for a subset — “start low and note” is common advice. forum
  • + Caffeine + L-theanine: Classic study-stack layer for alertness without pure caffeine edge; watch stacked overstim with higher Noopept. forum
  • + Other racetams: Piracetam, phenylpiracetam, oxiracetam, aniracetam, or nefiracetam in older poly-racetam logs — heavy confound and higher side risk. forum
  • + Semax (or N-Acetyl Semax / NASA): Frequent “Russian cognitive stack” pairing — Noopept oral + Semax nasal; multi-agent attribution messy. forum
  • + Selank (or N-Acetyl Selank Amidate): Calm/anxiolytic peptide with Noopept focus lore — often same course calendar as Semax+Selank pairs. forum
  • Exam-day polypharmacy examples: Community write-ups sometimes reserve Semax + Selank nasal plus Noopept on test day after multi-week prep stacks — not a studied protocol. anecdote
  • + Phenylpiracetam pulse: Occasional high-demand day pairing (e.g. Noopept with phenylpiracetam every few days in one popular log style) — stim load and tolerance concerns rise. anecdote
  • Lifestyle co-credits: Sleep, training, and deliberate study blocks often co-credited more than the molecule alone. forum
  • Solo-first habit: Many experienced users introduce Noopept alone for several days before stacking so headache/stim/sleep can be attributed. forum

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 15

  • Headache (community #1): Most frequent self-reported downside; usually blamed on choline demand — many add Alpha-GPC or CDP-choline; some get no headache at all. Not a trial-established mechanism. forum
  • Brain fog / paradoxical fatigue: Opposite of intended clarity in a subset — dose, choline excess, sleep debt, or mislabeled product often debated. forum
  • GI / nausea: Occasional stomach discomfort, nausea, or heartburn in community and secondary side-effect lists. forum
  • Dizziness / dry mouth: Less common but listed in secondary nootropic reviews at higher consumption. forum
  • Mood polarity: Clinical literature stresses anxiolytic components; community splits between calmer baseline vs anxiogenic overstim — individual variation dominates. forum
  • Source quality risk: Contamination, wrong identity, under/over-fill, and degraded powder are structural gray-market problems; file presence of a COA is not automatic proof of what is in the jar. forum
  • Russian Rx ≠ Western research chem: Different manufacturing and regulatory paths; do not assume equivalent safety labeling. forum
  • Not risk-free: Short half-life and “well tolerated” trial language do not equal zero CNS, CV, or product-quality risk; silence in a forum log is not safety proof. forum
  • Irritability / overstimulation: Restlessness, edginess, or anxiety-adjacent feel — more common at higher daily totals or late dosing; conflicts with the “anxiolytic” clinical framing for some users. forum
  • Sleep disturbance: Insomnia, vivid dreams, or delayed onset — appears in both trial AE lists and community logs, especially with afternoon/evening doses. trial
  • Trial AE rates (NCATS / related clinical summary for ~BID oral courses in unhealthy adults): Sleep disturbance grade 1–2 ~16.1%; irritability grade 1 ~9.7%; increased blood pressure grade 2–3 ~9.7%; headache grade 1 ~3.2%; chest pain grade 1 ~3.2% — small open cohorts, not large placebo-controlled incidence. trial
  • Blood pressure: Minority BP rise in vascular-MCI / organic brain disease trial populations — flag for CV-sensitive contexts; not characterized as a controlled risk in healthy young users. trial
  • Long-term / healthy-user gap: Longest commonly cited controlled human courses ~56 days in impaired populations; continuous multi-year healthy enhancement safety tables do not exist. trial
  • Evidence concentration: Much foundational preclinical and clinical work sits near the Russian originating program — internally consistent but thinly independently replicated at scale. trial
  • Pregnancy / interactions / special populations: Not robustly characterized in modern Western databases; research-only framing applies. trial

Updated: 2026-08-12

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →